← Back to Search

Muscarinic Receptor Antagonist

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Phase 1
Waitlist Available
Research Sponsored by Cerevel Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (0.5, 1.5 and 2.0 hours)
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how CVL-231, a drug targeting brain receptors, works in healthy adults. The goal is to understand its effects on specific brain areas before using it to treat schizophrenia.

Eligible Conditions
  • Schizophrenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (0.5, 1.5 and 2.0 hours)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 (0.5, 1.5 and 2.0 hours) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
M4 receptor occupancy in the striatum following single oral doses of CVL-231 in healthy adult subjects
Secondary study objectives
AUCscan duration for CVL-231
Cavg/Scan duration for CVL-231
Cmax during scan for CVL-231
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CVL-231Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CVL-231
2022
Completed Phase 1
~300

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Cerevel Therapeutics, LLCLead Sponsor
36 Previous Clinical Trials
5,527 Total Patients Enrolled
7 Trials studying Schizophrenia
2,011 Patients Enrolled for Schizophrenia
Matthew Leoni, MD, MBAStudy DirectorCerevel Therapeutics, LLC
2 Previous Clinical Trials
89 Total Patients Enrolled
1 Trials studying Schizophrenia
16 Patients Enrolled for Schizophrenia
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top